Farxiga heart failure study

Farxiga (dapagliflozin) is used for adults with heart failure with reduced ejection fraction. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure. LONDON, Aug 27 (Reuters) - AstraZeneca's (AZN. A pooled analysis of DELIVER and another trial involving about 11,000 heart failure patients combined showed Farxiga reduced the risk of death from cardiovascular causes – including heart attacks –. 5 † All cases of diabetic ketoacidosis occurred in patients with diabetes at baseline. L) blockbuster diabetes drug Farxiga led to significant reductions in the risk of hospitalisation and death in people with all types of heart failure,. 8 million patient-years’ experience. 5%), total (first and repeat) farxiga heart failure study hospitalisation for hf by 29% (p < 0. 2%), and urinary tract infections (5. Farxiga is for reducing the risk of hospitalization for heart failure or cardiovascular-related death.. FARXIGA helps provide life-saving protection by reducing the risk of CV death and hospitalization for heart failure 1 FARXIGA is the ONLY SGLT2i that significantly reduced the risk of the individual components of CV death and hospitalization for heart failure 1,4-6. 001, arr 6%), and farxiga heart failure study the composite of death from cv causes, myocardial infarction, or …. 01, absolute risk reduction [arr] 1. FARXIGA has a proven safety profile * Severe hypoglycemia defined as hypoglycemia requiring the assistance of another person to actively administer carbohydrates, glucagon, or take other corrective action. Farxiga was shown in a clinical trial to improve survival and reduce the need for hospitalization in adults with heart failure with reduced ejection fraction. FARXIGA is a prescription medicine used to: improve blood sugar control along with diet and exercise in adults with type 2 diabetes reduce the risk of hospitalization for heart failure in adults with type 2 diabetes and known cardiovascular disease or multiple cardiovascular risk factors. The analysis showed that farxiga reduced the risk of cv death by 14% (p=0. McMurray JJV, DeMets DL, Inzucchi SE, et al. These data build upon our previous studies demonstrating cardiorenal protection across patients with either diabetes, chronic kidney disease or heart failure. 5%) over the median follow-up of 22 months, death from farxiga heart failure study any cause by 10% (p=0. Dapagliflozin in patients with heart failure and reduced ejection fraction. Farxiga’s safety and effectiveness. About AstraZeneca in heart failure. Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. 4 Farxiga has a robust clinical trial programme exploring highly prevalent and interconnected diseases, including diabetes, heart failure and chronic kidney disease across more than 35 completed and ongoing Phase IIb/III trials in over 35,000 patients, as well as more than 1. Eur J Heart Fail 2021; 23(7):1217–25. It is specifically for those with Class II through IV heart failure, according to the New York Heart Association (NYHA) heart failure guidelines. The primary endpoint is time-to-first cardiovascular death or worsening heart failure event (heart failure hospitalization or urgent heart failure visit), and will be assessed in dual primary analyses - the full population and in those with LVEF. In a pool of 12 placebo-controlled studies, the most common adverse reactions (≥5%) associated with FARXIGA 5 mg, 10 mg, and placebo respectively were female genital mycotic infections (8. N Engl J Med 2019; 381(21):1995–2008.

Alternatives to farxiga

farxiga heart failure study farxiga heart failure study